137 related articles for article (PubMed ID: 36516201)
1. Evaluation of cell collection efficiency in non-mobilized adult donors for autologous chimeric antigen receptor T-cell manufacturing.
Piñeyroa JA; Cid J; Vlagea A; Carbassé G; Henao P; Bailo N; Ortiz-Maldonado V; Martínez-Cibrian N; Español M; Delgado J; Urbano-Ispizua Á; Lozano M
Vox Sang; 2023 Mar; 118(3):217-222. PubMed ID: 36516201
[TBL] [Abstract][Full Text] [Related]
2. Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients.
Jarisch A; Rettinger E; Sörensen J; Klingebiel T; Schäfer R; Seifried E; Bader P; Bonig H
J Clin Apher; 2020 Sep; 35(5):398-405. PubMed ID: 32750197
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
Ceppi F; Rivers J; Annesley C; Pinto N; Park JR; Lindgren C; Mgebroff S; Linn N; Delaney M; Gardner RA
Transfusion; 2018 Jun; 58(6):1414-1420. PubMed ID: 29536556
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.
Tuazon SA; Li A; Gooley T; Eunson TW; Maloney DG; Turtle CJ; Linenberger ML; Connelly-Smith LS
Transfusion; 2019 May; 59(5):1773-1780. PubMed ID: 30729531
[TBL] [Abstract][Full Text] [Related]
5. Leukocytapheresis in nonmobilized donors for cellular therapy protocols: Evaluation of factors affecting collection efficiency of cells.
Cid J; Carbassé G; Alba C; Perea D; Lozano M
J Clin Apher; 2019 Dec; 34(6):672-679. PubMed ID: 31487075
[TBL] [Abstract][Full Text] [Related]
6. Evolution of MNC and lymphocyte collection settings employing different Spectra Optia
Punzel M; Kozlova A; Quade A; Schmidt AH; Smith R
Vox Sang; 2017 Aug; 112(6):586-594. PubMed ID: 28809049
[TBL] [Abstract][Full Text] [Related]
7. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
Cells; 2020 May; 9(5):. PubMed ID: 32429189
[TBL] [Abstract][Full Text] [Related]
8. First comparative evaluation of a new leukapheresis technology in non-cytokine-stimulated donors.
Steininger PA; Strasser EF; Weiss D; Achenbach S; Zimmermann R; Eckstein R
Vox Sang; 2014 Apr; 106(3):248-55. PubMed ID: 24152115
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic donor peripheral blood "stem cell" apheresis: prospective comparison of two apheresis systems.
Brauninger S; Bialleck H; Thorausch K; Felt T; Seifried E; Bonig H
Transfusion; 2012 May; 52(5):1137-45. PubMed ID: 22044384
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures.
Sanderson F; Poullin P; Smith R; Nicolino-Brunet C; Philip P; Chaib A; Costello R
J Clin Apher; 2017 Jun; 32(3):182-190. PubMed ID: 27442837
[TBL] [Abstract][Full Text] [Related]
11. Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.
Harrer DC; Heidenreich M; Fante MA; Müller V; Haehnel V; Offner R; Burkhardt R; Herr W; Edinger M; Wolff D; Thomas S; Brosig A
Transfusion; 2022 Aug; 62(8):1602-1611. PubMed ID: 35851959
[TBL] [Abstract][Full Text] [Related]
12. Comparison between intermittent and continuous leukapheresis protocols for autologous hematopoietic stem cell collections in children.
Ali S; Chiang KY; Even-Or E; Di Mola M; Schechter T; Ali M; McDougall E; Svajger G; Licht C; Krueger J
J Clin Apher; 2019 Dec; 34(6):646-655. PubMed ID: 31424127
[TBL] [Abstract][Full Text] [Related]
13. The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy.
Arat M; Arslan O; Gürman G; Dalva K; Ozcan M; Uğur A; Ilhan O
Transfus Apher Sci; 2004 Feb; 30(1):9-15. PubMed ID: 14746816
[TBL] [Abstract][Full Text] [Related]
14. [Clinical experience of leukapheresis for CD19 CAR-T cell therapy].
Jo T; Yoshihara S; Arai Y; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Matsui K; Niwa N; Nakagawa Y; Kitawaki T; Kanda J; Takaori-Kondo A; Nagao M
Rinsho Ketsueki; 2021; 62(3):163-169. PubMed ID: 33828008
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients.
Long G; Waller EK; Gregurek S; Tricot G; Marschner S; Bill J
J Clin Apher; 2015 Feb; 30(1):1-7. PubMed ID: 24941931
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Spectra Optia apheresis system for mononuclear cell (MNC) collection in G-CSF mobilized and nonmobilized healthy donors: results of a multicenter study.
Karafin MS; Graminske S; Erickson P; Walters MC; Scott EP; Carter S; Padmanabhan A
J Clin Apher; 2014 Oct; 29(5):273-80. PubMed ID: 24677347
[TBL] [Abstract][Full Text] [Related]
17. Comparison of hematopoietic progenitor cell collection using different inlet flow rates with the Fenwal Amicus.
Burgstaler EA; Bryant SC; Winters JL
J Clin Apher; 2022 Jun; 37(3):206-216. PubMed ID: 35018671
[TBL] [Abstract][Full Text] [Related]
18. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.
Jo T; Yoshihara S; Hada A; Arai Y; Kitawaki T; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Obi N; Matsui K; Niwa N; Nakagawa Y; Kanda J; Kondo T; Saida S; Kato I; Hiramatsu H; Adachi S; Takita J; Takaori-Kondo A; Nagao M
Transplant Cell Ther; 2022 Jul; 28(7):365.e1-365.e7. PubMed ID: 35460928
[TBL] [Abstract][Full Text] [Related]
19. Optia® continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE® spectra system: A retrospective study.
Pandey S; Cottler-Fox M
J Clin Apher; 2018 Aug; 33(4):505-513. PubMed ID: 29603795
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients.
Hutt D; Bielorai B; Baturov B; Z'orbinski I; Ilin N; Adam E; Itzhaki O; Besser MJ; Toren A; Jacoby E
Transfus Apher Sci; 2020 Aug; 59(4):102769. PubMed ID: 32414613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
